About
Artificial intelligence has reached another significant milestone in pharmaceutical research with Rentosertib (formerly ISM001-055/INS018_055) becoming the first AI-designed drug to enter a Phase III clinical trial. Developed by Insilico Medicine, the drug was discovered using the company’s AI-powered Pharma.AI platform, which identified a novel therapeutic target and designed the molecule in a fraction of the time required by conventional drug discovery.
Rentosertib is being developed for Idiopathic Pulmonary Fibrosis (IPF), a progressive and life-threatening lung disease with limited treatment options. Unlike existing therapies that primarily slow disease progression, the AI-designed drug targets TNIK (Traf2- and NCK-interacting kinase), offering a potentially new mechanism for treating fibrosis.
The ongoing Phase III study is a randomized, double-blind, placebo-controlled clinical trial expected to enroll approximately 320 patients over 52 weeks to evaluate the drug’s safety and efficacy. The trial follows encouraging Phase IIa results, where patients receiving Rentosertib demonstrated improvements in lung function compared with placebo.
What AI Changed
- AI identified a promising new drug target (TNIK).
- Generative AI designed and optimized the drug molecule.
- Discovery-to-clinic timeline was reduced to approximately 18 months, significantly faster than traditional drug discovery.
What AI Did Not Change
While AI accelerated the discovery process, every stage of clinical development continues to rely on human expertise, including:
- Clinical trial design
- Patient recruitment
- Safety monitoring
- Regulatory compliance
- Statistical analysis
- Data quality and validation
The drug must still meet the same regulatory standards required for any new medicine before approval. AI assists discovery—it does not replace rigorous clinical research.
The advancement of Rentosertib into Phase III demonstrates the growing role of artificial intelligence in pharmaceutical innovation while reinforcing that robust clinical trials remain essential for proving a drug’s safety and effectiveness.